Koninklijke Philips (PHIA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 Jul, 2026Opening remarks and agenda
The meeting opened with acknowledgment of global geopolitical tensions and their impact on operations in over 70 countries.
Legal and statutory requirements for the meeting were confirmed as met, with 81% of share capital represented.
Voting was conducted electronically throughout the meeting, with shareholders able to change votes until after agenda item 9.
Financial performance review
Solid progress was reported for 2025, including improved order intake, comparable sales growth, margin expansion, and strong cash flow.
Disciplined cost management and productivity improvements contributed to financial results.
A new three-year plan (2026–2028) was launched, targeting 4–6% average growth, mid-teens margin, and significant cash flow growth.
Board and executive committee updates
Roy Jakobs' reappointment as CEO was proposed and later approved, with emphasis on leadership and progress.
Supervisory Board members, including new nominee John DeFord, were introduced and their roles outlined.
Latest events from Koninklijke Philips
- Strong margin gains and resilient performance offset flat sales and China demand weakness.PHIA
Q3 20249 Jul 2026 - All AGM proposals passed with strong support amid ongoing focus on resilience, ESG, and innovation.PHIA
AGM 20259 Jul 2026 - Margin expansion and higher free cash flow drive improved 2025 outlook despite ongoing risks.PHIA
Q2 20258 Jul 2026 - Q3 2025 saw 8% order intake growth, 3% sales growth, and margin expansion to 12.3%.PHIA
Q3 20258 Jul 2026 - Targeting mid-single-digit growth and mid-teens margins by 2028 through AI-driven platforms and execution.PHIA
CMD 20261 Jul 2026 - Q1 2026 delivered strong sales and margin growth, with guidance reaffirmed amid global risks.PHIA
Q1 20269 May 2026 - Strong 2025 growth and margin gains set up for higher sales and profitability in 2026.PHIA
Q4 202510 Feb 2026 - Q2 saw 2% sales growth, 9% order intake rise, margin gains, and major Respironics settlements.PHIA
Q2 20242 Feb 2026 - AI-driven health innovation and open platforms fuel growth and ESG leadership.PHIA
Show & Tell 202420 Jan 2026